Slingshot members are tracking this event:

Celgene (CELG) expects topline data readout in mid-2018 for Phase 3 luspatercept study in patients at low risk Myelodysplastic syndromes (MDS)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
CELG Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 09, 2018
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Topline Data, Luspatercept, Myelodysplastic Syndromes